Drugs / BTA-C585
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02718937 | Mar → Dec 2016 | respiratory syncytial virus infectious disease | Biota Pharma Europe Limited | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT02668367 Comparator | Nov 2015 → Feb 2016 | — | Biota Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02558413 Comparator | Aug → Dec 2015 | — | Biota Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BTA-C585 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02668367 ↗ |
| Route | Oral | “BTA-C585 administered orally to healthy subjects.” NCT02558413 ↗ |